Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Boehringer Ingelheim
McKesson
AstraZeneca
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,282,966

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,282,966 protect, and when does it expire?

Patent 8,282,966 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-two patent family members in six countries.

Summary for Patent: 8,282,966
Title:Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.
Inventor(s): Baldassarre; James S. (Doylestown, PA), Rosskamp; Ralf (Chester, NJ)
Assignee: INO Therapeutics LLC (Hampton, NJ)
Application Number:12/821,020
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,282,966
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 8,282,966

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-002 Dec 23, 1999 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,282,966

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009202685   Start Trial
Australia 2010202422   Start Trial
Australia 2010206032   Start Trial
Australia 2012201382   Start Trial
Australia 2015100638   Start Trial
Australia 2015100783   Start Trial
Australia 2015202617   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.